Dechow A, Timonen S, Ianevski A, Jiang Q, Wahnschaffe L, Peng Y, Jungherz D, Becker K, Neubauer HA, Schönefeldt S, de Araujo E, Gunning P, Fleck R, Schrader A, Hallek M, Pflug N, Moriggl R, Aittokallio T, Mustjoki S, Braun T, Herling M (2025)
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia
Leukemia (in press)
DOI 10.1038/s41375-025-02577-8, PubMed 40234614

Tanoli Z, Fernández-Torras A, Özcan UO, Kushnir A, Nader KM, Gadiya Y, Fiorenza L, Ianevski A, Vähä-Koskela M, Miihkinen M, Seemab U, Leinonen H, Seashore-Ludlow B, Tampere M, Kalman A, Ballante F, Benfenati E, Saunders G, Potdar S, Gómez García I, García-Serna R, Talarico C, Beccari AR, Schaal W, Polo A et al. (2025)
Computational drug repurposing: approaches, evaluation of in silico resources and case studies
Nat Rev Drug Discov (in press)
DOI 10.1038/s41573-025-01164-x, PubMed 40102635

Yin Y, Xu H, He L, Brown JR, Mato AR, Aittokallio T, Skånland SS (2025)
Protein profiles predict treatment responses to the PI3K inhibitor umbralisib in patients with chronic lymphocytic leukemia
Clin Cancer Res (in press)
DOI 10.1158/1078-0432.CCR-24-2911, PubMed 40085050